Duality Advisers LP Purchases New Shares in DexCom, Inc. (NASDAQ:DXCM)

Duality Advisers LP purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 41,321 shares of the medical device company's stock, valued at approximately $5,128,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Bartlett & CO. Wealth Management LLC purchased a new stake in DexCom during the 4th quarter valued at $27,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Harbour Investments Inc. grew its position in DexCom by 55.6% in the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company's stock valued at $31,000 after acquiring an additional 120 shares during the last quarter. Atlas Capital Advisors LLC bought a new position in DexCom in the 2nd quarter valued at $33,000. Finally, MV Capital Management Inc. grew its position in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 2.7 %

DexCom stock traded down $3.59 during midday trading on Friday, reaching $130.71. The company's stock had a trading volume of 2,859,646 shares, compared to its average volume of 2,337,474. The stock's 50-day simple moving average is $129.55 and its 200-day simple moving average is $117.04. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The stock has a market capitalization of $50.39 billion, a P/E ratio of 99.78, a PEG ratio of 2.25 and a beta of 1.20.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the business posted $0.34 earnings per share. The company's revenue for the quarter was up 26.9% compared to the same quarter last year. On average, sell-side analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Activity at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the firm's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company's stock, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research analyst reports. Citigroup upped their price objective on DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a research report on Wednesday, April 3rd. StockNews.com raised DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They issued an "outperform" rating and a $165.00 price objective on the stock. UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a "buy" rating in a research report on Wednesday, April 10th. Finally, Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $141.40.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.